Selective suppression of Toll-like receptor 4 activation by chemokine receptor 4  by Kishore, Sandeep P. et al.
FEBS 29202 FEBS Letters 579 (2005) 699–704Selective suppression of Toll-like receptor 4 activation
by chemokine receptor 4
Sandeep P. Kishorea, Marlo K. Bunguma, Jeﬀrey L. Platta,b,*, Gregory J. Brunna,c
a Transplantation Biology, Mayo Clinic, 200 First Street SW, Medical Sciences 2-66, Rochester, MN 55905, USA
b Departments of Immunology, Surgery, Pediatrics, Mayo Clinic, Rochester, MN 55905, USA
c Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN 55905, USA
Received 23 November 2004; revised 24 November 2004; accepted 20 December 2004
Available online 30 December 2004
Edited by Frances ShannonAbstract The response of Toll-like receptor 4 (TLR4) to lipo-
polysaccharide (LPS) is thought vital for resisting infection.
Since aberrant TLR4 signaling may initiate inﬂammatory condi-
tions such as the sepsis syndrome, we sought a component of nor-
mal cells that might provide local control of TLR4 activation.
We found that antibodies that block chemokine receptor 4
(CXCR4) function enhanced TLR4 signaling, while increased
expression of CXCR4 or addition of the CXCR4 ligand SDF-1
suppressed TLR4 signaling induced by LPS. These ﬁndings sug-
gest that CXCR4 could exert local control of TLR4 and suggest
the possibility of new therapeutic approaches to suppression of
TLR4 function.
 2004 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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As expressed on leukocytes, endothelial cells and various
parenchymal cells, Toll-like receptor 4 (TLR4) detects the
products of microorganisms, such as lipopolysaccharide
(LPS) [1–3], and endogenous substances, such as heparan sul-
fate and hyaluronic acid [4,5]. Following detection of these
substances, TLR4 transduces signals leading to activation of
NFjB, among other signaling pathways [6], that induce the
expression of genes that incite inﬂammation and adaptive
immunity. These responses sequester and clear microorgan-
isms and heighten resistance of the host upon re-infection
[7,8].
The inﬂammatory and immune responses triggered by TLR4
must be vital to host defense as they are induced by nanomolar
concentrations of LPS and mice with mutations that preclude
function or expression of TLR4 have marked susceptibility to
infection with Gram negative bacteria [2]. However, the func-Abbreviations: TLR, Toll-like receptor; CXCR4, chemokine receptor
4; LPS, lipopolysaccharide; SDF-1, stromal-cell derived factor-1;
NFjB, nuclear factor kappa B; SLPI, secretory leucoprotease inhib-
itor; HSP, heat shock protein
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doi:10.1016/j.febslet.2004.12.047tion of TLR4 is not always beneﬁcial. Widespread activation
of TLR4 gives rise to the ‘‘sepsis syndrome’’ characterized
by shock, multi-organ failure and death [9]. Aberrant activa-
tion of TLR4 has also been implicated in chronic inﬂamma-
tory diseases such as atherosclerosis [10], asthma [11],
osteoporosis and even obesity [12].
If activation of TLR4 is to beneﬁt the host and the sys-
temic changes in physiology characteristic of sepsis or chronic
inﬂammation are to be avoided, activation should be limited
to sites of infection (where microorganisms and their antigens
are present) and constrained at remote locations, where
microorganisms and antigens are lacking. To a certain extent,
such local control of TLR4 might be achieved through the
function of the secretory leucoprotease inhibitor (SLPI), a
protein that blocks TLR4-activated intracellular signals
[13,14]. However, SLPI is found mainly in secretions on epi-
thelial cell surfaces and thus would not prevent unwanted
activation of TLR4 in most tissue spaces. Given the need
to control activation of TLR4 at sites remote from infection,
we sought normal cellular constituents that might regulate
TLR4 function.
TLR4 exists and functions as a receptor complex, which
in addition to TLR4 includes MD2 and CD14 [15]. Other
cell surface proteins, including heat shock proteins (HSP)
70 and HSP90, growth and diﬀerentiation factor 5 and che-
mokine receptor 4 (CXCR4), can participate in TLR4 sig-
naling [16,17]. How these proteins function as a putative
‘‘LPS activation cluster’’ is not known, although HSP70
and HSP90 may do so by processing LPS [18,19] or by act-
ing directly on TLR4 [20–22]. Of these potential regulators,
CXCR4 has a dual function as, independent of any impact
on TLR4, it promotes migration of antigen presenting cells
outside of blood vessels and into secondary lymphatic or-
gans. We reasoned that this dual function of CXCR4 and
the positioning between innate and adaptive immunity
[23,24] would make CXCR4 a good candidate for an intrin-
sic regulator of TLR4 function. We report the testing of that
concept.2. Materials and methods
2.1. Sources of reagents and antibodies
LPS from Escherichia coli was obtained from Sigma–Aldrich (St.
Louis, MO). A neutralizing monoclonal antibody speciﬁc for chemo-
kine receptor 4 was from R&D Systems Inc. (Minneapolis, MN).blished by Elsevier B.V. All rights reserved.
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allophycocyanin (APC) were from BD Biosciences (San Diego, CA).
Fluorescein isothiocyanate (FITC)-conjugated antibodies were from
Southern Biotechnology Association (Birmanhgam, Alabama). Anti-
mouse TLR4/MD-2 was from BioSource (Camarillo, CA). Pertussis
Toxin (Bordatella Pertussis) and Pertussis Toxin-B (apoenzyme) were
from CalBiochem (La Jolla, CA). All materials used in cell culture were
certiﬁed endotoxin free or were treated with endotoxin removal resin
and tested by the Limulus amoebocyte lysate assay gel clot method (Sei-
kagaku, Falmouth, MA) to assure absence of detectable endotoxin.
2.2. Plasmid construction
Expression vectors encoding components of the TLR4 complex were
prepared as follows. Total RNA isolated from the murine macrophage
cell line RAW 264.7 (American Type Culture Collection, Manassas,
VA) was used to generate cDNA using the ‘‘1st Strand cDNA Synthe-
sis Kit’’ (Roche, Indianapolis, IN) for RT-PCR (AMV) with oligo(dt)
primers, according to the manufacturers recommended protocol. The
resulting pool of cDNA was used as a template in polymerase chain
reactions (PCRs) to amplify sequences encoding TLR4, MD2 and
CD14, using ‘‘Expand High Fidelity’’ polymerase (Roche). TLR4
was ampliﬁed using the primers: TLR4 Forward 5 0-CGC GGA TCC
AGG ATG ATG CCT CCC TGG CTC-3 0 and TLR4 Reverse 5 0-Fig. 1. Activation of TLR4 in HEK 293 cells. Whether CXCR4 modiﬁes TLR
using monoclonal antibodies and testing the eﬀect of this treatment on TLR4
stably transfected with murine TLR4, MD2 and CD14 expression plasmids
cells). The cells were then characterized and tested as shown in the ﬁgure. (A
TLR4(+) cells was determined by ﬂow cytometry using anti-CXCR4 or contro
TLR4(+) cells express CXCR4. (B) Stimulation of HEK 293 cells by LPS an
lack TLR4) were transfected with NFjB-ﬁreﬂy luciferase and internal contro
ng/ml of LPS, 10 lg/ml of heparan sulfate, or 10 ng/ml recombinant human
stimulation, results shown are means of triplicate wells. These results, which a
respond to LPS and heparan sulfate. (C) Impact of CXCR4 on activation o
activate TLR4, HEK/TLR4(+) cells were transfected with NFjB- and con
CXCR4 monoclonal antibodies or control antibodies of the same isotype fo
HEK/TLR4(+) response was measured by NFjB-activated luciferase expre
antibodies enhanced responsiveness of HEK/TLR4(+) cells to LPS.GGC GGT ACC TCA GGT CCA AGT TGC CGT TTC-3 0. MD2
was ampliﬁed using MD2 forward 5 0-CCG GAA TTC ATC ATG
TTG CC-3 0 and MD2 reverse 5 0-CCG GAA TTC CTA ATT GAC
ATC ACG-3 0. CD14 was ampliﬁed using CD14 forward 5 0-CCG
GAA TTC ACC ATG GAG CGT GTG CTT GGC-3 0 and CD14 re-
verse 5 0-CCG GAA TTC TTA AAC AAA GAG GCG ATC TCC
TAG-3 0. PCR products were cloned into eukaryotic expression plas-
mids (Invitrogen, Carlsbad, CA): TLR4 into pcDNA3.1, MD2 into
pcDNA3.1/Hygro CD14 into pcDNA4/myc-His with zeocin resistance.
Cloned sequences were screened for correct orientation and sequence.
A NFjB-ﬁreﬂy luciferase reporter plasmid was obtained from Dr. Car-
los Paya (Mayo College of Medicine, Rochester, MN). Control Renil-
la-luciferase reporter plasmid was pTK-Renilla (Promega, Madison,
WI). The YFP-CXCR4 expression plasmid was prepared by cloning
the CXCR4 coding sequence [25] into the pEYFP-C1 vector (Clontech,
Palo Alto, CA) with the vector encoded yellow ﬂuorescent protein ap-
pended in frame with the carboxy-terminus of the CXCR4 coding
sequence.
2.3. Cell cultures
HEK 293 cells (human embryonic kidney cells) from American
Type Culture Collection (ATCC) were cultured in DMEM contain-
ing 10% fetal bovine serum, penicillin and streptomycin. HEK 2934 activation was tested by measuring the impact of perturbing CXCR4
activation by LPS in HEK 293 cells. For this end, HEK 293 cells were
and cell lines that express these proteins were selected (HEK/TLR4(+)
) CXCR4 expression on HEK/TLR4(+). CXCR4 expression on HEK/
l APC-conjugated monoclonal antibodies. The results show that HEK/
d heparan sulfate. HEK/TLR4(+) cells or control HEK 293 cells (that
l Renilla-luciferase reporter plasmids and then tested for response to 10
IL-1a. NFjB-activated luciferase expression was measured 4 h after
re representatives of three experiments, show that HEK/TLR4(+) cells
f TLR4 by LPS. To determine if CXCR4 aﬀects the ability of LPS to
trol-luciferase reporter plasmids and then treated with 25 lg/ml anti-
r thirty minutes, after which the indicated amount of LPS was added.
ssion determined six hours after addition of LPS. The anti-CXCR4
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mids using the Superfect transfection reagent (Qiagen, Valencia,
CA), as suggested by the manufacturer for stable transfection.
TLR4/MD2/CD14 expressing HEK 293 cells were selected using
appropriate antibiotic selection medium and were then cloned by
limiting dilution in the same medium. Control cells were prepared
using empty expression vectors and identical transfection and selec-
tion procedures.
2.4. Stimulation of HEK 293 cells
HEK 293 cell lines stably expressing TLR4/MD2/CD14 were seeded
into 24-well tissue culture plates (2 · 105 cells/well) and allowed to ad-
here at 37 C overnight. The adherent cells were transfected with 0.1 lg
pTK-Renilla luciferase and 0.1 lg NFjB-ﬁreﬂy luciferase using Super-
fect Transfection Reagent (Qiagen) and then cultured for 24 h at 37 CFig. 2. Eﬀect of enhanced expression of CXCR4 on TLR4 activation. To
TLR4(+) cells were transfected with a vector encoding human CXCR4 fus
plasmids, along with NFjB- and control-luciferase reporter plasmids and res
TLR4(+) cells transfected with CXCR4-YFP. HEK/TLR4(+) cells were trans
of the cells was determined using an anti-CXCR4 monoclonal antibody con
ﬂuorescence (lower panel). These results demonstrate that HEK/TLR4(+) cell
level than controls. (B) Enhanced expression of CXCR4 decreases respon
transfected with CXCR4-YFP or control expression vectors along with NFj
cells to LPS was determined. Some samples were treated with 25 lg/ml of an
with LPS. HEK/TLR4(+) cells transfected with CXCR4 did not respond to LP
CXCR4 antibodies activated the NFjB-luciferase reporter fully. These result
activation by LPS. (C) Control of TLR4 signaling by CXCR4 is speciﬁc for L
HEK/TLR4(+) cells were transfected with CXCR4 or control expression
responsiveness to heparan sulfate, an endogenous activator of TLR4, was test
CXCR4 monoclonal antibodies, did not aﬀect activation of HEK/TLR4(+)
interferes with activation of TLR4 by LPS.in 1 mL DMEM containing 0.5% fetal bovine serum. The cells were
stimulated as indicated, washed with phosphate buﬀered saline and
lysed with 150 lL Passive Lysis Buﬀer (Promega). The amount of Re-
nilla- and Fireﬂy luciferase in the cell lysates was assayed simulta-
neously using Dual-Luciferase Reporter Assay System (Promega)
and a TD-20/20 lumenometer (Turner Designs, Sunnyvale, CA). Acti-
vation of NFjB-ﬁreﬂy luciferase reporter activity is given as the ratio
of ﬁreﬂy luciferase to the internal control Renilla-luciferase activity,
determined and expressed as the mean of triplicate wells.
2.5. Flow cytometry
Flow cytometric analysis was performed as described by Kodaira
et al. [26]. HEK 293 cells were incubated with APC-conjugated anti-
CXCR4 monoclonal antibodies and analyzed by FACScan using Cell-
Quest software (Becton–Dickinson, San Jose, CA).determine whether CXCR4 diminishes responsiveness to LPS, HEK/
ed to yellow ﬂuorescent protein (CXCR4-YFP) or control expression
ponsiveness to LPS was determined. (A) CXCR4 expression in HEK/
fected with CXCR4-YFP vector and CXCR4 expression on the surface
jugated to APC (upper panel) or by directly measuring CXCR4-YFP
s transfected with CXCR4-YFP express CXCR4 at about 5-fold higher
siveness of HEK/TLR4(+) cells to LPS. HEK/TLR4(+) cells were
B- and control-luciferase reporter plasmids and responsiveness of the
ti-CXCR4 monoclonal antibodies (anti-CXCR4) prior to stimulation
S. HEK/TLR4(+) cells transfected with CXCR4 and treated with anti-
s indicate that cell surface expression of CXCR4 interferes with TLR4
PS. To determine if suppression of TLR4 by CXCR4 is speciﬁc to LPS,
plasmids and NFjB- and control-luciferase reporter plasmids and
ed. CXCR4 expression, or neutralization of CXCR4 function with anti-
cells by heparan sulfate. This result indicates that CXCR4 speciﬁcally
LPS (ng/ml)
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Fig. 3. Eﬀect of signaling by CXCR4 on TLR4 activation. To
determine if the inhibitory eﬀect of CXCR4 on TLR4 activation
requires signaling by CXCR4, HEK/TLR4(+) cells were transfected
with NFjB- and control-luciferase reporter plasmids and treated with
the CXCR4 agonist SDF-1, or with pertussis toxin (PT), an inhibitor
of CXCR4 signaling, prior to stimulating the cells with LPS. (A)
CXCR4 signaling inhibits TLR4 activation by LPS. To determine if
CXCR4 signaling inhibits TLR4 activation by LPS, HEK/TLR4(+)
cells were transfected with NFjB- and control-luciferase plasmids and
treated with 50 nM SDF-1, an agonist of CXCR4, and stimulated with
the indicated concentrations of LPS. Stimulation of CXCR4 by SDF-1
suppressed TLR4 activation by LPS. (B) Eﬀect of Pertussis toxin on
activation of TLR4 by LPS. To determine which signals from CXCR4
inhibit activation of TLR4 by LPS, HEK/TLR4(+) cells were
transfected with NFjB- and control-luciferase plasmids and treated
with 0.1 lg/ml pertussis toxin (PT), which inhibits CXCR4 signaling by
modifying receptor-associated Gi. Controls included HEK/TLR4(+)
cells treated with the pertussis toxin B oligomer (PT-B), which binds to
cells but does not inhibit CXCR4 signaling. Pertussis toxin did not
enhance but instead inhibited LPS-stimulated HEK/TLR4(+) activa-
tion. These results indicate that signaling by CXCR4 inhibits activa-
tion of TLR4 by LPS, and this eﬀect is likely mediated by the bc
component of CXCR4.
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3.1. CXCR4 and the TLR4 response to LPS
Since CXCR4 is found in the ‘‘LPS activation cluster’’
[16,17] and can interact with other cell surface receptors, we
asked whether it might inﬂuence activation of TLR4. To deter-
mine whether CXCR4 inﬂuences TLR4 activation by LPS, we
developed a model using HEK 293 cells, which naturally ex-
press CXCR4 (Fig. 1A) but not TLR4 (not shown). The
HEK 293 cells were made to express deﬁned components of
the TLR4 complex [15] by transfection with vectors encoding
murine TLR4, MD2, and CD14 and selection of clones that
stably express these proteins (HEK/TLR4(+) cells, data not
shown). HEK 293 cells transfected this way respond to LPS
and heparan sulfate (Fig. 1B).
To determine whether CXCR4 inﬂuences activation of
TLR4 by LPS, HEK/TLR4(+) cells were transfected with
NFjB-ﬁreﬂy luciferase and internal control Renilla-luciferase
reporter plasmids and then the impact of inhibition of CXCR4
on TLR4 signaling was measured. As Fig. 1C shows, when
HEK/TLR4(+) cells were treated with anti-CXCR4 antibodies
that perturb the conformation and function of the receptor, re-
sponses to low concentrations of LPS (less than 3 ng/ml) were
increased nearly 2-fold compared to HEK/TLR4(+) cells trea-
ted with control IgG. Anti-CXCR4 antibodies did not modify
activation of HEK/TLR4(+) by higher concentrations of LPS
(10 ng/ml). This result suggests that CXCR4 raises the thresh-
old for TLR4 activation.
If CXCR4 inhibits activation of TLR4 by LPS, we reasoned
that overexpression of CXCR4 might potentiate the inhibition.
To test this possibility, we transfected HEK/TLR4(+) cells
with a plasmid vector encoding human CXCR4 and the
NFjB- and control-luciferase reporter plasmids and tested re-
sponses to LPS. The HEK/TLR4(+) cells transfected with
CXCR4 expressed that protein at 5-fold greater levels than
controls (Fig. 2A) did not respond to LPS (Fig. 2B). To con-
ﬁrm that heightened expression of CXCR4 and not some other
factor suppressed TLR4 signaling, we treated HEK/TLR4(+)
cells that had been transfected with CXCR4 with anti-CXCR4
monoclonal antibodies and then stimulated the cells with LPS.
As Fig. 2B shows, HEK/TLR4(+) cells transfected with
CXCR4 and treated with anti-CXCR4 antibodies responded
by activating the NFjB-luciferase reporter, conﬁrming that
CXCR4 had suppressed TLR4 signaling.
To determine if CXCR4 must be activated to suppress
stimulation of TLR4 by LPS, we tested whether increasing
availability of SDF-1, the agonist for CXCR4 [27], would
potentiate inhibition of HEK/TLR4(+) cell responses to
LPS. As Fig. 3 shows, when HEK/TLR4(+) cells were stim-
ulated simultaneously with LPS and SDF-1, the cells were
indiﬀerent to the presence of LPS at any concentration
tested (Fig. 3A). SDF-1 by itself initiated a slight activation
of the luciferase reporter, consistent with ﬁndings that
CXCR4 is a weak stimulator of NFjB [28], but this level
of activation is far below that observed for LPS treatment
alone. Treatment of HEK/TLR4 cells with SDF-1 did not al-
ter expression of TLR4 (not shown), suggesting that signals
delivered through CXCR4 strongly inhibit activation of
TLR4 signaling by LPS.
We next asked whether the inhibition of TLR4 by CXCR4
is speciﬁc for LPS. To address this question, HEK/TLR4(+)
cells transfected with CXCR4 and NFjB- and control-lucif-erase reporter plasmids were tested for response to heparan
sulfate, an endogenous activator of TLR4 [4]. As shown in
Fig. 2C, HEK/TLR4(+) cells responded fully to heparan sul-
fate despite overexpression of CXCR4, and treatment of
HEK/TLR4(+) cells with anti-CXCR4 antibodies did not
inﬂuence responsiveness to heparan sulfate. These results
indicate that CXCR4 speciﬁcally constrains signaling by
TLR4 induced by LPS. Failure of CXCR4 to inhibit activa-
tion of TLR4 by heparan sulfate has several potential expla-
nations. Heparan sulfate may act somewhat diﬀerently on
S.P. Kishore et al. / FEBS Letters 579 (2005) 699–704 703TLR4 than does LPS, as previous work suggests [4]. Alterna-
tively, the added soluble heparan sulfate might elute SDF-1
from its cellular attachments, primarily heparan sulfate pro-
teoglycans on the cell surface [29], and prevent the SDF-1-
stimulated TLR4-inhibitor function.
If signaling by CXCR4 suppresses activation of TLR4 by
LPS, we reasoned that interference with CXCR4 signaling
should enhance HEK/TLR4(+) activation by LPS. To test
this possibility, we treated HEK/TLR4(+) cells with pertussis
toxin, a protein that inhibits signaling of G proteins such as
Gi associated with CXCR4 [30], and tested responses of the
cells to LPS. As Fig. 3B shows, pertussis toxin did not en-
hance HEK/TLR4 activation by LPS, rather treatment of
HEK/TLR4(+) cells with pertussis toxin diminished TLR4
activation by LPS. Since inhibition of CXCR4-associated
Gi by pertussis toxin did not increase activation of TLR4
by LPS, the inhibitory signal delivered by CXCR4 is likely
mediated by the bc subunit of this heterotrimeric G-protein
coupled receptor.
The ﬁndings presented here indicate that interaction of SDF-
1 and CXCR4 with TLR4 raises the threshold for activation of
inﬂammatory cells by TLR4. This change in threshold does
not prevent activation of TLR4 by ‘‘large’’ amounts of LPS,
but it may prevent inadvertent activation by trace amounts,
as may occur at tissue sites remote from the site of infection.
Our ﬁndings may explain why local infections with Gram neg-
ative bacteria usually do not cause the systemic manifestations
of sepsis. Since the CXCR4 expression did not change the
threshold for activation of TLR4 by heparan sulfate, other lo-
cal controls must exist for this agonist. Consistent with that
possibility, we have recently found that activation of TLR4
by heparan sulfate is suppressed by intact extracellular matrix
and relieved by degradation of matrix by proteases (unpub-
lished observations).
CXCR4 may coordinate a delicate balance between pro-
moting and inhibiting inﬂammation. SDF-1 acting on
CXCR4 directs migration of CD3+ lymphocytes into areas
of inﬂammation, and recent evidence demonstrates that this
pro-inﬂammatory property of SDF-1 is silenced by prote-
ases secreted by activated neutrophils [31]. The results we
report suggest that SDF-1 and CXCR4 may also limit
inappropriate inﬂammatory cues by raising the activation
threshold for TLR4. The interplay between the pro- and
anti-inﬂammatory properties of SDF-1, CXCR4, and
TLR4 oﬀers new targets to potentially manipulate immune
function.Acknowledgment: This work was supported by grants from the Na-
tional Institutes of Health (HL46810 and AI53733).References
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